The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Fedyaeva V.K.

Center for Expertise and Quality Control of Medical Care;
Financial Research Institute

Ryzhov A.O.

Center for Expertise and Quality Control of Medical Care;
Russian Medical Academy of Continuous Professional Education

Efficacy of dapagliflozin and empagliflozin for prevention of cardiovascular complications in patients with type 2 diabetes mellitus: a network meta-analysis

Authors:

Fedyaeva V.K., Ryzhov A.O.

More about the authors

Journal: Medical Technologies. Assessment and Choice. 2022;44(4): 42‑50

DOI: 10.17116/medtech20224404142

Read: 15351 times

Download PDF (RU)
Contact the author
Table of contents

EFFICACY OF DAPAGLIFLOZIN AND EMPAGLIFLOZIN FOR PREVENTION OF CARDIOVASCULAR COMPLICATIONS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A NETWORK META-ANALYSIS
EFFICACY OF DAPAGLIFLOZIN AND EMPAGLIFLOZIN FOR PREVENTION OF CARDIOVASCULAR COMPLICATIONS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A NETWORK META-ANALYSIS

To cite this article:

Fedyaeva VK, Ryzhov AO. Efficacy of dapagliflozin and empagliflozin for prevention of cardiovascular complications in patients with type 2 diabetes mellitus: a network meta-analysis. Medical Technologies. Assessment and Choice. 2022;44(4):42‑50. (In Russ.)
https://doi.org/10.17116/medtech20224404142

Подписка 2026 Медицинские технологии. Оценка и выбор (Medical Technologies. Assessment and Choice)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Cost-effectiveness analysis of remote glycemic moni­toring in patients with diabetes mellitus in the Russian Fede­ration. Medi­cal Technologies. Asse­ssment and Choice. 2026;(1):92-102
Ranking of mechanical thro­mboprophylaxis methods in surgery: a network meta-analysis. Medi­cal Technologies. Asse­ssment and Choice. 2026;(1):143-152
Ethnic aspe­cts of risk factors for the type 2 diabetes mellitus deve­lopment in the overweight women of the Pribaikalsky region. Russian Journal of Preventive Medi­cine. 2025;(8):56-62
Asse­ssment of biomarker levels in patients with STEMI, depe­nding on the presence of cardiovascular events. Russian Journal of Preventive Medi­cine. 2025;(8):96-101
Sex and age characteristics of stroke risk factors in patients with type 2 diabetes mellitus. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8-2):89-97
Possibilities of oral form of cyanocobalamin in pharmacological correction of vita­min B12 defi­ciency deve­loped in patients with type 2 diabetes mellitus during treatment with metformin. Russian Journal of Preventive Medi­cine. 2025;(9):64-69
Rela­tionship between heart rate and patients with type 2 diabetes death. Russian Journal of Preventive Medi­cine. 2025;(11):14-22
Prospects for Nagu­tskaya no. 26 mine­ral water in correction of carbohydrate and lipid meta­bolism in patients with insu­lin resi­stance. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2025;(4):20-28
The role of the Diabetes School in increasing compliance of patients with type 2 diabetes to treatment and improving glycemic control. Russian Journal of Preventive Medi­cine. 2026;(1):47-53
Comparative effi­cacy of therapy with SGLT-2 inhi­bitors and bariatric surgery in patients with class I obesity and type 2 diabetes. Endo­scopic Surgery. 2026;(1):5-12
Abstract:

OBJECTIVE

A network meta-analysis (indirect comparison and mixed comparison) of the effects of empagliflozin and dapagliflozin on the incidence of adverse cardiovascular outcomes in patients with type 2 diabetes mellitus (DM2) and previous cardiovascular diseases.

MATERIAL AND METHODS

A systematic review and selection of studies were performed in the PubMed and EMBASE databases. A network meta-analysis was performed in accordance with the guidelines for indirect comparisons and criteria for assessing the methodological quality of indirect comparisons. Indirect comparisons were made using the methodology presented by H.C. Bucher et al. (1997).

RESULTS

We enrolled 3 randomized controlled trials (RCTs) for inclusion in indirect comparison network (one RCT for empagliflozin and two RCTs for dapagliflozin). Moreover, additional searching revealed one head-to-head comparative real-life study of dapagliflozin and empagliflozin that was included in a mixed comparison network. We found no difference in clinical efficacy of dapagliflozin and empagliflozin for preventing adverse cardiovascular events in patients with DM2 and previous cardiovascular diseases.

Keywords:

type 2 diabetes mellitus
dapagliflozin
empagliflozin
network meta-analysis

Authors:

Fedyaeva V.K.

Center for Expertise and Quality Control of Medical Care;
Financial Research Institute

Ryzhov A.O.

Center for Expertise and Quality Control of Medical Care;
Russian Medical Academy of Continuous Professional Education

Received:

14.09.2022

Accepted:

11.10.2022

Close metadata

References:

  1. Dedov II, Shestakova MV, Vikulova OK. Epidemiology of diabetes mellitus In Russian Federation: clinical and statistical report according to the federal diabetes registry. Saharnyj diabet. 2017;20(1):13-41. (In Russ.). https://doi.org/10.14341/DM8664
  2. Klinicheskie rekomendacii Saharnyj diabet 2 tipa u vzroslyh. Rossijskaya associaciya endokrinologov. 2022. (In Russ.). https://cr.minzdrav.gov.ru/recomend/290_2
  3. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31-39.  https://doi.org/10.1016/S0140-6736(18)32590-X
  4. Castellana M, Procino F, Sardone R, Trimboli P, Giannelli G. Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis. Cardiovascular Diabetology. 2020;19(1):1-10.  https://doi.org/10.1186/s12933-020-01067-8
  5. Wu JH, Foote C, Blomster J, Toyama T, Perkovic V, Sundström J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. The Lancet. Diabetes and Endocrinology. 2016;4(5):411-419.  https://doi.org/10.1016/S2213-8587(16)00052-8
  6. Li C, Liang Sh, Gao L, Liu H. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: a real-world systematic review and meta-analysis. PloS ONE. 2021;16(2):e0244689. https://doi.org/10.1371/journal.pone.0244689
  7. Rebrova OYu, Fedyaeva VK., Khachatryan GR. Adaptation and Validation of the Cochrane Questionnarie to Assess Risks of Bias in Randomized Controlled Trials. Medicinskie tekhnologii. Ocenka i vybor. 2015;19(1):9-17. (In Russ.).
  8. Omelyanovskiy VV, Avxentyeva MV, Sura MV, Khachatryan GR, Fedyaeva VK. Metodicheskie rekomendacii po provedeniyu nepryamyh sravnenij lekarstvennyh preparatov. M. 2017. (In Russ.).
  9. Rebrova OYu, Fedyaeva VK. Questionnaire for assessing the reliability of network meta-analysis (including indirect and mixed comparisons). Medicinskie tekhnologii. Ocenka i vybor. 2016;24(2):9-15. (In Russ.).
  10. Bucher HC, Gordon H, Lauren EG, Walter SD. The Results of Direct and Indirect Treatment Comparisons in Meta-Analysis of Randomized Controlled Trials. Journal of Clinical Epidemiology. 1997;50(6):683-691.  https://doi.org/10.1016/s0895-4356(97)00049-8
  11. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, EMPA-REG OUTCOME Investigators, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine. 2015;373(22):2117-2128. https://doi.org/10.1056/NEJMoa1504720
  12. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine. 2019;380(4):347-357.  https://doi.org/10.1056/NEJMoa1812389
  13. Petrie MC, Verma S, Docherty KF, Inzucchi SE, Anand I, Belohlávek J, et al. Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. Jama. 2020;323(14):1353-1368. https://doi.org/10.1001/jama.2020.1906
  14. Shao SC, Chang K-Ch, Hung M-J, Yang N-I, Chan Y-Y, Chen H-Yu, et al. Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi- institutional cohort study. Cardiovascular Diabetology. 2019;18(1):1-15.  https://doi.org/10.1186/s12933-019-0919-9
  15. Rebrova OYu. Statisticheskij analiz medicinskih dannyh. Primenenie paketa prikladnyh programm Statistica. M.: Media Sfera; 2006. (In Russ.).
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.